Abstract: A method of promoting weight loss in animals or humans by administering thereto a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed.
Type:
Grant
Filed:
March 31, 2010
Date of Patent:
December 6, 2011
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, Karl Reuter, Viktor Meier, Florian Stolz, Eliso Gogritchiani
Abstract: Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration of formulations containing therapeutically effective amounts of an adrenergic beta-receptor agonist to said patients. In particular, certain embodiments disclosed herein concern compositions that contain R-salbutamol as the active beta-receptor stimulating ingredient. In certain embodiments, the formulations are administered to the ocular surface of the eye and/or to the eyelid (the underside of the eyelid and/or the top of the eyelid) of a patient in need thereof.
Abstract: Internal-dermal formulations of RS—, S—, or R-2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine causing intradermal accumulation of said piperidine and intended for the treatment of neuropathic pain are provided, as well as a method of inducing the relief of pain using the compounds.
Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.
Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
Type:
Grant
Filed:
February 12, 2009
Date of Patent:
January 18, 2011
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
Abstract: A method of promoting weight loss in animals or humans by administering thereto a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed.
Type:
Application
Filed:
March 31, 2010
Publication date:
July 22, 2010
Applicant:
BRIDGE PHARMA, INC.
Inventors:
A.K. Gunnar Aberg, Karl Reuter, Viktor Meier, Florian Stolz, Eliso Gogritchiani
Abstract: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.
Abstract: Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen.
Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
May 25, 2010
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, Karl Reuter, Viktor Meier, Florian Stolz, Eliso Gogritchiani
Abstract: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.
Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen.
Type:
Grant
Filed:
April 30, 2007
Date of Patent:
July 7, 2009
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
Abstract: Dermal and mucosal formulations of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine, characterized by rapid dermal and mucosal absorption and long duration of therapeutic activity are provided. Also provided are solutions of 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine for injection, characterized by short onset time and long duration of activity. Formulations containing both 2-[2-(N-phenyl-N-2-indanyl)aminoethyl]piperidine and capsaicin are also provided.
Abstract: Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.
Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal.
Abstract: Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of ketotifen.
Type:
Grant
Filed:
September 12, 2000
Date of Patent:
June 5, 2007
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, George E. Wright, Jan L. Chen, Andrew T. Maioli
Abstract: The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, and other smooth muscle contractility conditions. More particularly, the present invention relates to certain metabolically stabilized secondary amines having smooth muscle relaxing properties while avoiding, on administration to a mammal, adverse side effects such as prominent antimuscarinic, arrhythmogenic and cardiodepressive effects.
Type:
Grant
Filed:
May 21, 2004
Date of Patent:
November 28, 2006
Assignee:
Bridge Pharma, Inc.
Inventors:
A. K. Gunnar Aberg, Jan L. Chen, Andrew T. Maioli, George E. Wright
Abstract: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.
Abstract: The present invention relates to the R-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep.
Abstract: Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with other antimuscarinic drugs.
Abstract: A method of treating disorders involving the urethrogentical tract by administering to pateints in need therof therapeutically effective amounts of the desethyl metabolite of oxybutynin and/or the optically active isomers thereof, which are free from said cardiac side effect of oxybutynin, while maintaining the therapeutic activities of oxybutynin or the optically active isomers thereof.